Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126328 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Filipa Amaro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Kidney Neoplasms, Protein Kinase Inhibitors, Sunitinib. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, Research Unit on Applied Molecular Biosciences-UCIBIO, Associate Laboratory Institute for Health and Bioeconomy-i4HB.
Abstract (Originalsprache)
The development of resistance to tyrosine kinase inhibitors (TKIs) is a major cause of treatment failure in metastatic renal cell carcinoma (mRCC). A deeper understanding of the metabolic mechanisms associated with TKI resistance is critical for refining therapeutic strategies. In this study, we established resistance to sunitinib and pazopanib by exposing a parental Caki-1 cell line to increasing concentrations of sunitinib and pazopanib. The intracellular and extracellular metabolome of sunitinib- and pazopanib-resistant mRCC cells were investigated using a nuclear magnetic resonance (NMR)-based metabolomics approach. Data analysis included multivariate and univariate methods, as well as pathway and network analyses. Distinct metabolic signatures in sunitinib- and pazopanib-resistant RCC cells were found for the first time in this study. A common metabolic reprogramming pattern was observed in amino acid, glycerophospholipid, and nicotinate and nicotinamide metabolism. Sunitinib-resistant cells exhibited marked alterations in metabolites involved in antioxidant defence mechanisms, while pazopanib-resistant cells showed alterations in metabolites associated with energy pathways. Sunitinib-resistant RCC cells demonstrated an increased ability to proliferate, whereas pazopanib-resistant cells appeared to restructure their energy metabolism and undergo alterations in pathways associated with cell death. These findings provide potential targets for novel therapeutic strategies to overcome TKI resistance in mRCC through metabolic regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Associate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.
- UCIBIO-Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
- RISE-UFP, Health Research Network, Faculty of Health Sciences, University Fernando Pessoa, 4200-150 Porto, Portugal.
ORCID-Profile: Márcia Carvalho, Paula Guedes de Pinho, Joana Pinto
Förderung
- Fundação para a Ciência e Tecnologia
- Research Unit on Applied Molecular Biosciences-UCIBIO
- Associate Laboratory Institute for Health and Bioeconomy-i4HB
- FCT
- Scientific Employment Stimulus
Zitieren
APA
Amaro, F., Carvalho, M., Bastos, M. L., Guedes de Pinho, P., & Pinto, J. (2024). Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126328
Vancouver
Amaro F, Carvalho M, Bastos ML, Guedes de Pinho P, Pinto J. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126328
BibTeX
@article{Amaro2024,
author = {Amaro, Filipa and Carvalho, Márcia and Bastos, Maria de Lourdes and Guedes de Pinho, Paula and Pinto, Joana},
title = {Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126328}
}
EUVIMED